Beritasatu.com – Virus vaccine corona developed by the University of Oxford, UK, records a number of breakthroughs which are by far the most concrete, so far after the clinical trial stages 1 and 2 have passed.
According to the release of the British government which was continued by the British Embassy in Jakarta, there was a number of concrete evidences achieved in the clinical trial.
First, the vaccine is able to trigger a stable immune system response from 100% of the test object after being given two doses. In fact, 90% of them already produce antibodies at the first dose.
Second, there were no other health problems that arose during the trial.
Third, the vaccine has succeeded in activating both sides of the immune system at once. The vaccine triggers the production of white blood cells within 14 days of vaccination, and also antibodies within 28 days.
At present, phase 3 clinical trials involving children and other age groups have already begun in a number of countries, including the United States, Brazil and South Africa.
The vaccine manufacturing partner, pharmaceutical company AstraZeneca, expressed optimism about the efficacy of the vaccine and has received commitments to supply more than 2 billion doses to the UK, US, Europe, India and a number of global organizations.
The British government has invested £ 84 million to develop a virus vaccine corona. However, it was stated that not all of these investments were directed to just one producer, and still opened the door to other vaccines that promised as a precautionary measure.
In British government terms, as quoted by the embassy, the government does not “put all eggs in one basket”.
For example, the British government has also partnered with pharmaceutical companies and vaccine producers BioNTech / Pfizer and Valneva to develop vaccines corona separately.
For anyone
“The encouraging news from Oxford this week together with the successive announcements of those working on vaccines in Indonesia might be considered a moment when the waves finally turn around,” said British Deputy Ambassador to Indonesia Rob Fenn.
“It is still too early to declare victory indeed, but Oxford University is inhabited by great researchers from various parts of the world, and AstraZeneca is working on plans to mass produce this vaccine. Is it really this vaccine that will make a difference, or are other vaccines, the UK and Indonesia still stressing the importance of having an affordable and accessible vaccine for anyone, “he stressed.
The clinical trial results of the Oxford vaccine have been published in the scientific journal The Lancet.
It is said that this vaccine triggers the response of T cells (white blood cells) within 14 days to attack cells infected with Covid-19.
Then in a period of 28 days antibodies that can neutralize the virus appear so that they cannot infect other cells when the patient is first infected.
During the study, participants who were given the vaccine were detected raising important antibodies for protection.
It was stated in the journal that blood in 100% of participants showed neutralizing the virus corona. The next step is to ensure that this vaccine can effectively protect users from infection with SARS-CoV-2, the official name of the virus.
“Although there is still much that needs to be done, today’s data increases our confidence that this vaccine will work and enables us to continue producing vaccine plans that are widely and equally accessible worldwide,” said Mene Pangalos, vice president of biopharmaceutical research and development at AstraZeneca.
–
